OverviewSuggest Edit

SutroVax is a company that develops conjugate and novel complex antigen-based vaccines intended to prevent serious infectious diseases. SutroVax's cell-free protein synthesis platform permits site-specific conjugation, enabling the creation of conjugate vaccines with the potential to deliver heightened immunity and broader protection.
HQFoster City, CA, US

Latest Updates

Employees (est.) (Jan 2021)66(+7%)
Cybersecurity ratingAMore

Key People/Management at SutroVax

Grant Pickering

Grant Pickering

President & Chief Executive Officer, Director and Founder
Kurt von Emster

Kurt von Emster

Moncef Slaoui

Moncef Slaoui

Patrick Heron

Patrick Heron

Jim Wassil

Jim Wassil

Chief Operating Officer
Peter Hirth

Peter Hirth

Show more

SutroVax Office Locations

SutroVax has an office in Foster City
Foster City, CA, US (HQ)
353 Hatch Dr
Show all (1)

SutroVax Financials and Metrics

Summary Metrics

Founding Date


SutroVax total Funding

$281 m

SutroVax latest funding size

$110 m

Time since last funding

10 months ago

SutroVax investors

SutroVax's latest funding round in March 2020 was reported to be $110 m. In total, SutroVax has raised $281 m
Show all financial metrics

SutroVax Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

SutroVax Online and Social Media Presence

Embed Graph

SutroVax News and Updates

Eyeing the most lucrative vaccine market, SutroVax nabs $85M and Moncef Slaoui as chairman

With ambitions to take on global vaccine leaders in the industry's top field, SutroVax is revving up operations with Series C funding and a prominent Big Pharma ex as chair. The target? Pneumococcal vaccines such as Pfizer’s Prevnar.

Corporate Investment In Pharma Startups On The Rebound

Many of the most active investors in pharmaceutical startups are venture capital firms such as OrbiMed Advisors, NEA, or Versant Ventures. But direct investment from corporate entities and corporate venture arms has been trending up for the past 4 years. These … Continued

SutroVax Blogs

Vaxcyte to Present at Jefferies Virtual London Healthcare Conference

Vaxcyte to Present at Jefferies Virtual London Healthcare Conference Content Import Tue, 11/10/2020 - 16:41 Vaxcyte to Present at Jefferies Virtual London Healthcare Conference Nov 10, 2020 This release is a backfill from a News Wire General …

SutroVax Receives CARB-X Award for Up to $15 Million to Develop a Universal Vaccine to Prevent Group A Streptococcus Infections

Proprietary conserved antigen with potential to provide broad protection against strains of Group A Strep licensed from University of California San Diego Foster City, CA, September 3, 2019 – SutroVax,...

SutroVax Frequently Asked Questions

  • When was SutroVax founded?

    SutroVax was founded in 2013.

  • Who are SutroVax key executives?

    SutroVax's key executives are Grant Pickering, Kurt von Emster and Moncef Slaoui.

  • How many employees does SutroVax have?

    SutroVax has 66 employees.

  • Who are SutroVax competitors?

    Competitors of SutroVax include Biogen, MyoKardia and Athersys.

  • Where is SutroVax headquarters?

    SutroVax headquarters is located at 353 Hatch Dr, Foster City.

  • Where are SutroVax offices?

    SutroVax has an office in Foster City.

  • How many offices does SutroVax have?

    SutroVax has 1 office.